作者
Ananya Panda, Ishan Garg, Mark J Truty, Timothy L Kline, Matthew P Johnson, Eric C Ehman, Garima Suman, Deema A Anaam, Bradley J Kemp, Geoffrey B Johnson, Thorvardur R Halfdanarson, Sudhakar K Venkatesh, Jeff L Fidler, Ajit H Goenka
发表日期
2021/9/21
期刊
American Journal of Roentgenology
卷号
217
期号
3
页码范围
730-740
出版商
American Roentgen Ray Society
简介
BACKGROUND. Imaging biomarkers of response to neoadjuvant therapy (NAT) for pancreatic ductal adenocarcinoma (PDA) are needed to optimize treatment decisions and long-term outcomes.
OBJECTIVE. The purpose of this study was to investigate metrics from PET/MRI and CT to assess pathologic response of PDA to NAT and to predict overall survival (OS).
METHODS. This retrospective study included 44 patients with 18F-FDG–avid borderline resectable or locally advanced PDA on pretreatment PET/MRI who also underwent post-NAT PET/MRI before surgery between August 2016 and February 2019. Carbohydrate antigen 19-9 (CA 19-9) level, metabolic metrics from PET/MRI, and morphologic metrics from CT (n = 34) were compared between pathologic responders (College of American Pathologists scores 0 and 1) and nonresponders (scores 2 and 3). AUCs were measured for metrics significantly …
学术搜索中的文章
A Panda, I Garg, MJ Truty, TL Kline, MP Johnson… - American Journal of Roentgenology, 2021